Trials / Terminated
TerminatedNCT04261907
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- First Affiliated Hospital of Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in patients with 2019-nCoV pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASC09/ritonavir group | ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment |
| DRUG | lopinavir/ritonavir group | Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment |
Timeline
- Start date
- 2020-02-11
- Primary completion
- 2020-04-13
- Completion
- 2020-04-13
- First posted
- 2020-02-10
- Last updated
- 2022-04-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04261907. Inclusion in this directory is not an endorsement.